The British Business Bank has officially announced a €25 million ($28.6 million) investment into the EQT Health Economics 3 Fund (EQT HE3), a specialized vehicle managed by the prominent venture capital firm EQT Life Sciences. This strategic capital injection is designed to bolster the growth of high-potential medical technology and digital health companies across the United Kingdom and Europe, emphasizing the critical role of institutional support in scaling innovative healthcare solutions. The EQT HE3 fund, which has now reached a total size of €216 million since its launch in 2024, focuses on commercial-stage enterprises that aim to improve patient outcomes while enhancing the efficiency of healthcare delivery systems.
By channeling funds through EQT Life Sciences, the British Business Bank (BBB) is reinforcing its commitment to the UK’s Industrial Strategy, which identifies life sciences as one of eight key growth sectors vital to the nation’s long-term economic prosperity. The investment also marks a continuation of a productive relationship between the state-owned development bank and EQT, following several successful co-investments in British healthcare innovators.
Strategic Focus on Health Economics and Medtech
The EQT Health Economics 3 Fund is uniquely positioned within the venture capital landscape. Unlike traditional life sciences funds that may focus heavily on early-stage drug discovery—a process fraught with high failure rates and long development timelines—EQT HE3 targets companies that have already reached the commercialization stage. The fund’s primary focus is on medical technology (medtech), diagnostics, and digital health tools.
The "Health Economics" branding of the fund reflects a growing trend in global healthcare: the shift toward value-based care. Investors are increasingly looking for technologies that do not just treat diseases but do so in a way that reduces the overall financial burden on national healthcare providers, such as the UK’s National Health Service (NHS). By backing companies that offer cost-effective diagnostic tools or more efficient therapeutic devices, the fund aims to address the dual challenge of rising healthcare costs and aging populations.
The fund’s portfolio already includes several high-profile UK-based companies, such as Cyted Health and Phagenesis. These firms represent the exact type of "high potential" entities the British Business Bank seeks to support—companies with proven technologies that require significant capital to scale their operations and enter new international markets.
Strengthening the UK Life Sciences Ecosystem
The UK is globally recognized as a hub for life sciences, home to world-leading universities, a robust clinical research infrastructure, and a vibrant startup scene. However, a recurring challenge for British innovators has been the "scale-up gap"—the difficulty of securing large-scale growth capital to transition from a successful startup to a global market leader.
Christine Hockley, Managing Director and Head of Commercial Equity Funds at the British Business Bank, emphasized the necessity of specialist investment in this journey. According to Hockley, while the UK’s talent and research are world-class, the capital required to scale these companies often necessitates partnerships with international funds that possess deep sector expertise. By investing in EQT HE3, the British Business Bank ensures that UK-based companies can access not only capital but also the strategic guidance and global networks that a firm like EQT provides.
This investment is a key component of the BBB’s broader mandate to support the UK government’s Industrial Strategy. By fostering a fertile environment for life sciences, the bank aims to create high-skilled jobs, drive regional economic growth, and ensure that the UK remains at the forefront of medical innovation.
A History of Collaboration: Cyted Health and Phagenesis
The decision by the British Business Bank to commit to the EQT HE3 fund is rooted in a history of successful collaboration. The bank has previously participated in significant funding rounds for EQT’s portfolio companies, demonstrating a shared vision for the future of British medtech.
One notable example is Phagenesis, a Manchester-based medical device company that has developed the Phagenyx system. This innovative neurostimulation technology is designed to treat dysphagia (swallowing dysfunction), a common and serious complication following a stroke or prolonged mechanical ventilation. In 2023, the British Business Bank co-invested in Phagenesis’ $42 million Series D financing round. This capital was instrumental in helping the company expand its commercial footprint, particularly in the United States, where the clinical need for effective dysphagia treatments is immense.
Similarly, the bank supported Cyted Health during its $44 million Series B funding round in September 2025. Cyted Health is a digital diagnostic company focused on the early detection of gastrointestinal cancers. Its flagship product, the Heartbolt (often referred to as the "pill on a string" or Cytosponge), allows for the collection of esophageal cells in a non-invasive manner, providing an alternative to traditional endoscopies. By enabling earlier diagnosis of conditions like Barrett’s esophagus, Cyted’s technology can prevent the progression of esophageal cancer, saving lives and reducing the need for expensive, late-stage treatments.
These co-investments highlight the "multiplier effect" of the British Business Bank’s strategy. By partnering with private venture capital, the bank helps de-risk investments for other private actors, drawing more capital into the UK’s most promising tech sectors.
The Broader European Context and Institutional Support
The EQT HE3 fund is not only a British success story but a European one. In October 2025, the Dutch promotional bank, Invest-NL, committed €15 million to the fund, underscoring the collaborative nature of European healthcare investment. Like the British Business Bank, Invest-NL recognizes that medtech innovation requires a cross-border approach to achieve the scale necessary for global competition.
EQT Life Sciences itself has a formidable track record, having raised over €3.7 billion across 13 private funds to date. The firm has supported more than 150 companies, guiding them from early clinical development through to successful commercialization and, in many cases, public listings or acquisitions.
Beyond its UK interests, EQT has recently backed other European innovators, including:
- Neurent Medical: An Irish-headquartered company specializing in the treatment of chronic rhinitis through a minimally invasive handheld device.
- ViCentra: A Dutch developer of the Kaleido insulin pump, which is designed to be the smallest and lightest insulin patch pump on the market, significantly improving the quality of life for patients with Type 1 diabetes.
The inclusion of these companies in EQT’s broader strategy illustrates the fund’s commitment to "meaningful innovation"—technologies that provide tangible benefits to patients while fitting into the economic realities of modern healthcare systems.
Implications for the Future of Medtech Investment
The €25 million investment by the British Business Bank into EQT HE3 is more than just a financial transaction; it is a signal of confidence in the medtech sector. At a time when global venture capital markets have faced volatility, the continued support from institutional and state-owned banks provides a vital stabilizing force.
For the UK, the implications are clear. The government is signaling that it will use every tool at its disposal—including the British Business Bank’s commercial equity arm—to anchor the life sciences industry within its borders. This approach helps prevent "brain drain," where promising UK companies move their headquarters to the US or other regions in search of late-stage capital.
Furthermore, the focus on "health economics" suggests a maturing of the medtech sector. Investors are no longer just looking for the next "cool" gadget; they are looking for integrated solutions that solve systemic problems within healthcare. Companies that can prove their clinical efficacy while simultaneously demonstrating a clear "return on investment" for hospitals and insurers are the ones that will thrive in the current economic climate.
Official Reactions and Industry Sentiment
The partnership has been met with enthusiasm from both the public and private sectors. Drew Burdon, a partner at EQT Life Sciences, noted that the relationship with the British Business Bank has been built on years of mutual trust and successful co-investments. Burdon highlighted that the bank’s commitment to the HE3 fund will allow EQT to continue tapping into the "attractive UK health tech ecosystem," which remains a primary source of innovation for the firm.
Industry analysts suggest that this move will likely encourage other institutional investors, such as pension funds and insurance companies, to look more closely at the medtech space. The British Business Bank’s involvement serves as a "seal of approval," indicating that the fund has undergone rigorous due diligence and aligns with national strategic goals.
Conclusion: A Catalyst for Growth
As the EQT Health Economics 3 Fund continues to deploy its €216 million in capital, the impact on the UK and European healthcare landscape will be profound. The British Business Bank’s €25 million contribution acts as a catalyst, ensuring that companies like Cyted Health and Phagenesis have the resources they need to transform patient care on a global scale.
By bridging the gap between world-class research and commercial success, this investment reinforces the UK’s position as a global leader in life sciences. It ensures that the next generation of medical breakthroughs will not only be "Made in the UK" but will also be scaled and commercialized from the UK, benefiting the economy and, most importantly, the millions of patients who rely on these life-saving technologies.
